Results for the substance acalabrutinib

Acalabrutinib is a medication used to treat certain types of blood cancers, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other malignant lymphatic conditions. It belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors and works by blocking the activity of the BTK enzyme, which plays a key role in the survival and proliferation of cancerous B cells.

By inhibiting BTK, acalabrutinib reduces the growth and spread of cancer cells, helping to control disease progression. It is taken orally, usually in capsule form, twice daily as directed by a doctor.

Common side effects include headaches, fatigue, diarrhea, nausea, upper respiratory tract infections, and bruising. Rarely, more severe reactions such as major bleeding, serious infections, atrial fibrillation, or other cardiac issues may occur.

Patients taking acalabrutinib should be regularly monitored to assess the effectiveness of the treatment and to detect any adverse reactions. It is important to inform the doctor about other medications being taken, as acalabrutinib can interact with certain treatments, including anticoagulants and drugs that affect liver enzymes (CYP3A4).

Patients should also avoid consuming grapefruit or grapefruit juice, as it can increase the levels of the medication in the blood, raising the risk of side effects.